INVAP Chosen as Designer and General Contractor for Florida (EEUU)<\/p>\n
INVAP S.E. has signed with Coqu\u00ed RadioPharmaceuticals Corp., a medical isotope company working to become the first U.S. commercial producer of Molybdenum-99 (Mo-99)a contract to design its Medical Isotope Production Facility (“MIPF”) in Alachua, Florida. <\/p>\n
Mo-99 is the parent isotope of Technetium-99, which is used in 80 percent of nuclear medicine procedures worldwide. In 2012, Congress passed legislation making it a national priority to produce Mo-99, an isotope necessary to detect a wide range of diseases, including cardiovascular disease and cancer. <\/p>\n
Argentine nuclear engineering firm INVAP has been involved in nuclear development for more than 30 years. During that time it has worked on more than 15 nuclear reactors and related facilities across the world, including several reactors used to produce medical isotopes. Among these is the OPAL reactor in Australia, the ETRR-2 reactor in Egypt, and the NUR reactor in Algeria. Coqu\u00ed Pharma\u2019s MIPF will use an open pool reactor technology similar to that employed in the INVAP-designed OPAL facility in Australia.<\/p>\n
\u201cThe signing of this contract cements a key step in implementing proven technology to produce Mo-99 for patients requiring lifesaving medical diagnostics,\u201d said Carmen I. Bigles, Coqu\u00ed Pharma President and CEO. \u201cToday, Coqu\u00ed Pharma together with INVAP have built a bridge between the U.S. and Argentina, uniting our efforts to ensure the availability and reliability of the most essential radioisotope in nuclear medicine and with the added benefit of making the world a safer place for generations to come by utilizing proven non-proliferation,low-enriched uranium technologies.\u201d<\/p>\n
Coqu\u00ed Pharma is preparing its construction permit applicationfor submission to the U.S. Nuclear Regulatory Commission.Coqu\u00ed Pharma will utilize existing commercially proven technology with tested designs to license and build a facility that has the capability of reliably supplying a large portion of the U.S. market and international needs. <\/p>\n
Due to recent and future projected shortages, the issue of U.S. domestic medical isotope production has been discussed at great length within the industry and U.S. federal government.Coqu\u00ed Pharma reviewed options available to manufacture Mo-99 and determined that only the INVAP process provides a real, tangible and reliable solution to solve the medical isotope crisis<\/p>\n
+ INFORMATION<\/strong>
Coqui Radiopharmaceuticals<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"INVAP Chosen as Designer and General Contractor for Florida (EEUU) INVAP S.E. has signed with Coqu\u00ed RadioPharmaceuticals Corp., a medical isotope company working to become the first U.S. commercial producer of Molybdenum-99 (Mo-99)a contract to design its Medical Isotope Production Facility (“MIPF”) in Alachua, Florida. Mo-99 is the parent isotope of Technetium-99, which is used… View Article<\/a>","protected":false},"author":12,"featured_media":7768,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[24,29],"tags":[],"class_list":["post-6160","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-news","category-nuclear-medicine"],"acf":[],"yoast_head":"\n